Over the last decade, there has been a rising interest in the use of mesenchymal stem cells (MSCs) for clinical applications. This interest stems from the beneficial properties of MSCs, which include multi-lineage differentiation and immunosuppressive ability, suggesting there is a role for MSC therapy for tissue regeneration and in immunologic disease. Despite recent clinical trials investigating the use of MSCs in treating immune-mediated disease, their applicability in solid-organ transplantation is still unknown. In this review, we identified topics that are important when considering MSC therapy in clinical organ transplantation. Whereas, from other clinical studies, it would appear that administration of MSCs is safe, issues like dosing, timing, route of administration, and in particular the use of autologous or donor-derived MSCs may be of crucial importance for the functional outcome of MSCs treatment in organ transplantation. We discuss these topics and assess the feasibility of MSCs therapy in organ transplantation.

B lymphocyte, CD34 antigen, CD4 antigen, CD4+ T lymphocyte, CD40 antigen, CD72 antigen, CD8 antigen, CD8+ T lymphocyte, CD83 antigen, CD86 antigen, Cell therapy, HLA G antigen, Immune disease, Immune modulation, Immune therapy, Mesenchymal stem cell, Solid-organ transplantation, allogeneic stem cell transplantation, antigen expression, antigen presentation, antigen presenting cell, autologous stem cell transplantation, cell differentiation, cell lineage, cord blood stem cell transplantation, cyclosporin A, cytotoxic T lymphocyte, dendritic cell, feasibility study, gamma interferon, gamma interferon inducible protein 10, hematopoietic stem cell, human, immunocompetent cell, immunotherapy, intercellular adhesion molecule 1, intercellular adhesion molecule 2, interleukin 1, interleukin 10, interleukin 12, lymphocyte function associated antigen 3, mesenchymal stem cell, monocyte chemotactic protein, mononuclear cell, mycophenolic acid, natural killer cell, nitric oxide, nonhuman, organ transplantation, outcome assessment, peripheral blood, priority journal, prostaglandin E2, rapamycin, regulatory T lymphocyte, review, scatter factor, tacrolimus, tissue regeneration, transforming growth factor beta1, vascular cell adhesion molecule 1
dx.doi.org/10.1111/j.1432-2277.2008.00786.x, hdl.handle.net/1765/18155
Transplant International
Erasmus MC: University Medical Center Rotterdam

Crop, M.J, Baan, C.C, Weimar, W, & Hoogduijn, M.J. (2009). Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transplant International (Vol. 22, pp. 365–376). doi:10.1111/j.1432-2277.2008.00786.x